A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022

Ravi Kumar Gupta, Ashish Gupta, Jens Hillengass, Sarah A. Holstein, Vera J. Suman, Alankrita Taneja, Philip L. McCarthy

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Introduction: Recent advances in the diagnosis and management of multiple myeloma (MM) have improved patient outcomes. This progress in our understanding of MM has resulted in continuous suppressive therapy concepts, including induction, high dose chemotherapy with autologous stem cell transplantation (ASCT), consolidation, and maintenance therapy. The foundation of maintenance therapy has been with lenalidomide. Other novel immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and targeted monoclonal antibodies have also contributed to this evolution. Areas covered: This review summarizes the outcomes from phase II/III trials with long-term lenalidomide maintenance therapy alone or in combination with other agents in post-ASCT and non-transplant settings for newly diagnosed patients with MM. We review recent data considering a combination with newer medications and ongoing trials. We also review the optimal duration, MRD negativity rate, and safety and tolerability aspects of lenalidomide maintenance therapy. This review aims to present the current and emerging clinical evidence that supports using lenalidomide as a backbone for maintenance therapy in patients with MM. Expert opinion: There is increasing evidence to support lenalidomide as the backbone of combination therapy in the maintenance setting.

Original languageEnglish (US)
Pages (from-to)457-469
Number of pages13
JournalExpert review of anticancer therapy
Volume22
Issue number5
DOIs
StatePublished - 2022

Keywords

  • ASCT
  • Multiple myeloma
  • lenalidomide
  • maintenance therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022'. Together they form a unique fingerprint.

Cite this